Evidence map›Paper›PMID 35409289›Full record

ArticleInternational journal of molecular sciences2022

MicroRNA 3928 Suppresses Glioblastoma through Downregulation of Several Oncogenes and Upregulation of p53.

Elizabeth Q X Mulcahy, Ying Zhang, Rossymar R Colόn, Shelby R Cain, Myron K Gibert, Collin J Dube, Markus Hafner, Roger Abounader

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. How MicroRNAs Command the Battle against Cancer.International journal of molecular sciences · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Elizabeth Q X MulcahyDepartment of Microbiology, Immunology & Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA.
Ying ZhangDepartment of Microbiology, Immunology & Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA.
Rossymar R ColόnDepartment of Microbiology, Immunology & Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA.ORCID 0000-0001-7396-8045
Shelby R CainDepartment of Microbiology, Immunology & Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA.
Myron K GibertDepartment of Microbiology, Immunology & Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA.
Collin J DubeDepartment of Microbiology, Immunology & Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA.
Markus HafnerNational Institutes of Health (NIH), Bethesda, MD 20894, USA.
Roger AbounaderDepartment of Microbiology, Immunology & Cancer Biology, University of Virginia, Charlottesville, VA 22908, USA.
University of Virginia · USNational Institutes of Health · USUniversity of Virginia Cancer Center

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Dina Gould Halme · 1987 to 2026
$72.1M
Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
Integration of the results from systems-level determination of cis-acting elements into high-resolution maps of posttranscriptional regulatory events.ZIAAR041205 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI HAFNER, MARKUS · 2016 to 2025
$5.5M
The role of AU-rich element binding proteins in shaping target mRNA expressionZIAAR041200 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI HAFNER, MARKUS · 2014 to 2023
$5.1M
Master Regulatory MicroRNAs in GlioblastomaU01CA220841 · NCI · UNIVERSITY OF VIRGINIA · PI ABOUNADER, ROGER · 2017 to 2021
$2.5M
NCI NIH HHS Cancer Center Support Grant 5P30CA044579NCI NIH HHS P30 CA044579NCI NIH HHS T32 CA009109NCI NIH HHS U01 CA220841NIH HHS U01 CA220841
6 · The paper itself

Abstract

Glioblastoma (GBM) is the most frequent and lethal primary malignant brain tumor. Despite decades of research, therapeutic advances that significantly prolong life are non-existent. In recent years, microRNAs (miRNAs) have been a focus of study in the pathobiology of cancer because of their ability to simultaneously regulate multiple genes. The aim of this study was to determine the functional and mechanistic effects of miR-3928 in GBM both in vitro and in vivo. To the best of our knowledge, this is the first article investigating the role of miR-3928 in GBM. We measured endogenous miR-3928 expression levels in a panel of patient-derived GBM tissue samples and cell lines. We found that GBM tissue samples and cell lines express lower levels of miR-3928 than normal brain cortex and astrocytes, respectively. Therefore, we hypothesized that miR-3928 is a tumor suppressive microRNA. We verified this hypothesis by showing that exogenous expression of miR-3928 has a strong inhibitory effect on both cell growth and invasiveness of GBM cells. Stable ex vivo overexpression of miR-3928 in GBM cells led to a reduction in tumor size in nude mice xenografts. We identified many targets (MDM2, CD44, DDX3X, HMGA2, CCND1, BRAF, ATOH8, and BMI1) of miR-3928. Interestingly, inhibition of the oncogene MDM2 also led to an upregulation of wild-type p53 expression and phosphorylation. In conclusion, we find that miR-3928, through the downregulation of several oncogenes and upregulation and activation of wild-type p53, is a strong tumor suppressor in GBM. Furthermore, the fact that miR-3928 can target many important dysregulated proteins in GBM suggests it might be a "master" regulatory microRNA that could be therapeutically exploited.

Indexed as

GlioblastomaMicroRNAsAnimalsBasic Helix-Loop-Helix ProteinsDown-RegulationGene Expression Regulation, NeoplasticHumansMiceMice, NudeOncogenesTumor Suppressor Protein p53Up-RegulationBasic Helix-Loop-Helix ProteinsMicroRNAsTP53 protein, humanTumor Suppressor Protein p53BRAFCCND1CD44DDX3XglioblastomaHMGA2MDM2miR-3928p53

Identifiers

PMID35409289
PMCPMC8998958
OpenAlexW4223644744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.